Last reviewed · How we verify
IDP-108
IDP-108 is a small molecule that targets the SGLT2 receptor.
IDP-108 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | IDP-108 |
|---|---|
| Sponsor | Dow Pharmaceutical Sciences |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
IDP-108 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, such as canagliflozin and empagliflozin, which have been shown to improve glycemic control and reduce cardiovascular risk in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital mycotic infections
- Increased risk of urinary tract infections
- Hypotension
- Nausea
- Diarrhea
Key clinical trials
- Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis (PHASE3)
- The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis (PHASE3)
- A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-108 in Patients With Onychomycosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IDP-108 CI brief — competitive landscape report
- IDP-108 updates RSS · CI watch RSS
- Dow Pharmaceutical Sciences portfolio CI